We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

179 hedge funds and large institutions have $888M invested in Ariad Pharmaceuticals Inc in 2014 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 49 increasing their positions, 50 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 22

50% more funds holding in top 10

Funds holding in top 10: 46 (+2)

36% more capital invested

Capital invested by funds: $655M → $888M (+$233M)

6% more funds holding

Funds holding: 169179 (+10)

2% less repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 50

8% less call options, than puts

Call options by funds: $32M | Put options by funds: $34.7M

Holders
179
Holders Change
+10
Holders Change %
+5.92%
% of All Funds
4.77%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.16%
New
34
Increased
49
Reduced
50
Closed
22
Calls
$32M
Puts
$34.7M
Net Calls
-$2.74M
Net Calls Change
+$3.27M
Name Holding Trade Value Shares
Change
Change in
Stake
SCM
1
Sarissa Capital Management
Connecticut
$88.3M
Vanguard Group
2
Vanguard Group
Pennsylvania
$73.8M +$1.88M +300,266 +3%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$63.3M -$2.51M -402,000 -4%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$57.2M -$6.25M -1,000,000 -11%
Westfield Capital Management
5
Westfield Capital Management
Massachusetts
$57.1M +$52M +8,312,820 New
BFA
6
BlackRock Fund Advisors
California
$54.6M +$4.18M +669,032 +9%
CCM
7
Camber Capital Management
Massachusetts
$51.5M +$9.38M +1,500,000 +25%
State Street
8
State Street
Massachusetts
$39.8M -$417K -66,622 -1%
PC
9
PointState Capital
New York
$37.1M +$10.3M +1,650,000 +44%
BIT
10
BlackRock Institutional Trust
California
$33.7M +$554K +88,609 +2%
PI
11
Putnam Investments
Massachusetts
$22.5M +$18.8M +3,007,431 +1,100%
PAI
12
Palo Alto Investors
California
$15.3M
Northern Trust
13
Northern Trust
Illinois
$13.8M -$478K -76,364 -4%
CCI
14
Columbus Circle Investors
$13M -$2.68M -428,272 -18%
BNP Paribas Asset Management
15
BNP Paribas Asset Management
France
$12.2M +$1.5M +239,507 +16%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$11.8M +$1.48M +236,134 +16%
Ameriprise
17
Ameriprise
Minnesota
$11.7M +$488K +77,992 +5%
O
18
OppenheimerFunds
New York
$11.1M
OM
19
Opaleye Management
Massachusetts
$10.5M +$156K +25,000 +2%
Norges Bank
20
Norges Bank
Norway
$10.3M -$3.93M -627,761 -30%
AIMCA
21
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$9.48M +$8.63M +1,379,360 New
GAI
22
General American Investors
New York
$8.24M
HS
23
HighVista Strategies
Massachusetts
$8.24M
CC
24
CQS Cayman
Cayman Islands
$8.24M +$625K +100,000 +9%
ECP
25
Elk Creek Partners
Colorado
$7.92M +$3.08M +493,234 +75%

ARIA Hedge Fund Activity: Q4 2014 in Review

179 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q4 2014, worth a combined $888M — up 36% from $655M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new ARIA positions and 22 closed out — a net gain of 12 holders — while 49 added to existing stakes and 50 trimmed.

The largest buyer was Westfield Capital Management, opening a new position worth an estimated $52M. The largest seller was HealthCor Management, exiting entirely with an estimated $12.8M sold.

  • 179 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q4 2014, up from 169 in Q3 2014.
  • Funds reported $888M of Ariad Pharmaceuticals Inc stock for Q4 2014, up 36% quarter-over-quarter.
  • 34 funds opened new Ariad Pharmaceuticals Inc positions in Q4 2014 and 22 closed out, a net change of +12 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q4 2014 was Westfield Capital Management, an estimated $52M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q4 2014 was HealthCor Management, an estimated $12.8M sold.

Based on aggregated 13F filings for Q4 2014.